Vulcan Two Group (LSE:VUL), which is building a regulated UK ePharmacy platform through acquisition, said sales growth was strong in general healthcare, particularly women's health and ADHD medications, in the six months to 30 June.
The AIM-listed group acquired CloudRx, Hyperdrug and Webmed on 19 March, and has since cut a small number of lower-margin, higher credit-risk customers, mostly weight-loss clinics, a move it expects will reduce near-term revenue but lift gross margin percentage.
Point-of-order payments now account for 85% of revenues, supporting cash conversion and limiting bad-debt exposure.
The company reported cash balances of approximately £6.0 million at period end, alongside higher 2026 operating costs from early hires and double-running expenses that are expected to fall away in 2027.
Integration progress includes fit-out of a 22,000 sq ft Leeds distribution facility on track for year-end completion, ERP system integration, and the transfer of Webmed's fulfilment into CloudRx.
Keith Butcher joined as chief financial officer, and a naming agency has been appointed to unify the group's brand, with an announcement expected within weeks.
"We operate in a large, fragmented and fast-growing market with strong structural tailwinds", said chief executive Michael Kraftman, adding that the group's disciplined approach to acquisitions leaves it "well positioned to capitalise on the opportunity ahead."
News Intelligence what this means for the company
Vulcan Two Group has completed integration of its three March 2026 pharmacy acquisitions and is now actively pruning unprofitable customer segments—cutting low-margin, high-risk weight-loss clinics—to improve gross margin at the cost of near-term revenue. The move signals disciplined capital allocation and de-risks the balance sheet: 85% of revenues now come from point-of-order payments, sharply limiting bad-debt exposure and improving cash conversion. Integration milestones (Leeds distribution facility, ERP, Webmed fulfilment transfer) are on track, and the company has hired a CFO and appointed a naming agency, suggesting operational maturation.
The margin-for-growth trade-off is a positive signal of operational discipline, but the company's cash position of £6.0 million—half its September 2025 IPO proceeds—leaves limited runway for further acquisitions or to absorb the higher 2026 operating costs from integration and double-running expenses. Visibility on when those costs fall away in 2027, and on the scale of margin improvement, will be critical to validate the strategy.
Insights assembled by AI. Editor-reviewed and grounded in tickstock’s coverage and proprietary knowledge graph.
Content is for informational purposes only, not financial advice.
